Dive Brief:

简报：

Artis BioSolutions

艺思生物解决方案

emerged from stealth Wednesday,

周三脱离了秘密模式，

announcing that it has acquired Landmark Bio, an alliance of academic institutions, hospitals and biotech companies founded in 2021 to help turn research ideas into broadly available genetic medicines.

宣布已收购Landmark Bio，这家成立于2021年的联盟由学术机构、医院和生物技术公司组成，旨在帮助将研究构想转化为广泛可用的基因药物。

Landmark will continue to operate as a distinct entity, based in Watertown, Massachusetts. The acquisition by Artis BioSolutions will allow Landmark to scale up operations and “bring breakthrough therapies to more patients” Landmark CEO Ran Zheng

Landmark 将继续作为独立实体运营，总部位于马萨诸塞州沃特敦。Artis BioSolutions 的收购将使 Landmark 能够扩大运营规模，并“为更多患者带来突破性疗法”，Landmark 首席执行官郑然表示。

said in a statement

声明中说

.

。

Artis BioSolutions

艺缇斯生物解决方案

, backed by the venture capital firm Oak HC/FT, is now well positioned as a contract development and manufacturing organization for advanced therapies, the company said Wednesday. Artis BioSolutions said it can help customers speed up timelines, lower manufacturing costs and improve both product quality and supply chain management..

，这家风险投资公司 Oak HC/FT 表示，目前作为先进疗法的合同开发和制造组织处于非常有利的地位。Artis BioSolutions 表示，它可以帮助客户加快进度、降低生产成本并提高产品质量和供应链管理。

Dive Insight:

深度洞察：

Artis is launching at a critical time for genetic medicine research.

Artis 正在基因医学研究的关键时刻推出。

Funding

资金筹集

for developers of the therapies dropped in 2024 as investors looked for less risky bets. Meanwhile, Trump administration policies have led to mass firings at health agencies and the

2024年，随着投资者寻找风险较小的赌注，疗法开发者的数量下降。同时，特朗普政府的政策导致卫生机构大规模裁员和

departure

出发

of a key Food and Drug Administration official, Peter Marks, who was a champion of cell and gene therapies.

FDA高级官员彼得·马克斯是细胞和基因疗法的拥护者。

While genetic therapies hold incredible promise, they are also difficult to develop and produce. After a burst of investment in cell and gene therapy work, the industry in recent years has encountered shortages of the specialized facilities and manufacturing capacity needed to bring potential therapies to market..

虽然基因疗法蕴含着巨大的希望，但它们也难以开发和生产。近年来，在细胞和基因疗法领域的一波投资热潮之后，该行业遇到了将潜在疗法推向市场所需的专门设施和生产能力的短缺问题。

Along with larger players like Catalent and Lonza, a group of

像Catalent和Lonza这样的大公司，以及一群

startups

初创公司

including Landmark stepped into the breach. With founders ranging from Harvard University to Fujifilm Diosynth Biotechnologies,

包括朗德马克（Landmark）挺身而出。其创始人来自哈佛大学到富士胶片戴奥辛生物技术公司（Fujifilm Diosynth Biotechnologies）不等，

Landmark

地标

said its mission was to offer a “one-stop solution” for startups, with lab space, delivery tools like viral vectors and consulting for both drug development and regulatory issues.

表示其使命是为初创公司提供“一站式解决方案”，包括实验室空间、病毒载体等交付工具，以及药物开发和监管问题的咨询服务。

Together, Artis BioSolutions and Landmark have the “opportunity to transform biomanufacturing at scale,” Oak HC/FT partner Andy Smith said in the press release Wednesday.

奥克HC/FT合伙人安迪·史密斯在周三的新闻稿中表示，Artis BioSolutions和Landmark“有机会大规模转变生物制造”。

Artis BioSolutions is led by CEO

Artis BioSolutions 由首席执行官领导

Brian Neel

布赖恩·尼尔

and Chief Scientific Officer

首席科学官

Mike Houston

迈克·休斯顿

, both veterans of Maravai Life Sciences.

，两位都是马拉维生命科学公司的资深人士。